Search.
About Repligen. Investors. News. Pipeline. Products. Careers.

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. A number of drug development programs are currently being conducted to evaluate our drug candidates in diseases such as bipolar disorder and Friedreich's ataxia.

We currently market recombinant Protein A, which partially funds the advancement of our product development pipeline while supporting our financial stability.

Highlights

April 16, 2008
Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging more >

April 8, 2008
Repligen Announces Settlement with Bristol-Myers Squibb in Orencia® Lawsuit more >

March 26, 2008
Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging more >

February 7, 2008
Repligen Reports Third Quarter Fiscal Year 2008 Financial Results more >

Events

Conference Call to update Orencia® Lawsuit
Tuesday, April 8th, 2008 9:00 A.M. EDT

Dial-in: (866) 314-4865
International: (617) 213-8050
Passcode: 84470724
Listen to Webcast

Presentations

Repligen Presents at BIO CEO & Investor Conference
Monday, February 11th, 2008 2:00 P.M. EST

Listen to Webcast